<p><strong>Psyence Biomedical Ltd</strong> (NASDAQ:PBM) shares are trading lower in Wednesday’s premarket session. Nasdaq futures are up 0.71% while S&amp;P 500 futures have gained 0.56%.</p>



<h2>Investors Pivot to Profit-Taking</h2>



<p>The stock is currently experiencing a sharp reversal after soaring over 250% on Thursday. This massive rally was triggered by news that the White House is preparing an executive order to promote research into ibogaine. Investors appear to be engaging in profit-taking after the stock’s recent vertical climb.</p>



<h2>Trump Executive Order Boosts Sector</h2>



<p>The rally was sparked by President <strong>Donald Trump </strong>signing an executive order to accelerate mental illness treatments. The order specifically targets faster reviews for psychedelic drugs and includes a reported $50 million commitment for ibogaine research.</p>



<h2>Ibogaine Supply Chain Advantages</h2>



<p>Psyence Biomedical stands out due to its GMP-compliant ibogaine platform. Through PsyLabs, the company manages sourcing, extraction, and purification in Africa. Psyence is pitching itself as a rare picks-and-shovels supplier. The company already holds stabilized, pharmaceutical-grade ibogaine doses in its current inventory.</p>



<h2>Technical Analysis</h2>



<p>Psyence Biomedical is still trying to rebuild its longer-term chart after a deep drawdown, but the short-term trend has turned aggressive.</p>



<p>The stock is trading 115.3% above its 20-day simple moving average (SMA) and 68.7% above its 100-day SMA, which points to strong near-term momentum but also a more “stretched” distance that can invite snapback moves.</p>



<p>The relative strength index (RSI), a momentum gauge, is 78.66, which indicates overbought conditions and a higher risk of choppy pullbacks. RSI at 78.66 shows buyers have been in control lately, but it also signals momentum may be overheated.</p>



<p>Over the last 12 months, the stock is down 56.60%, which keeps the bigger-picture trend fragile despite the recent rebound. It’s also far below its 52-week high of $468.36 and above the 52-week low of $1.92, reinforcing that volatility has been extreme and trend confidence is still developing.</p>



<ul>
<li><strong>Key Resistance</strong>: $8.00 — a round-number area where sellers often show up first</li>



<li><strong>Key Support</strong>: $4.50 — near the 20-day EMA zone where dip-buyers may defend trend</li>
</ul>



<p><strong>PBM Stock Price Activity:</strong> Psyence Biomedical shares were down 15.17% at $8.05 during premarket trading on Wednesday, according to Benzinga Pro data.</p>



<p><em>Image via Shutterstock</em></p>

ARKG

SBIO

<p>Psyence Biomedical's stock is experiencing a significant decline of 15.17% in premarket trading, following a 250% surge last Thursday. This drop is attributed to profit-taking by investors after the stock's rapid rise, which was fueled by President Trump's executive order promoting ibogaine research. Despite the recent rally, the stock remains down 56.60% over the past year, indicating ongoing volatility. Key resistance is at $8.00, while support is at $4.50, as the stock attempts to stabilize after a deep drawdown.</p>

Why Is Psyence Biomedical Stock Falling Wednesday?